Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2022.1069999 Oncology Correction Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy Zhao Ni 1 Yi Ye 1 Cao Wen 2 Fu Xiao 1 Mei Nan 3 Li Chunli 1 * 1 Department of Medical Oncology, The First Affiliated Hospital of Xi’’an Jiaotong University, Xi’an, China 2 Department of Respiratory Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China 3 Department of Hematology. The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Edited and Reviewed by: Jun Zhang, University of Kansas Medical Center, United States

*Correspondence: Chunli Li, chunli5158@163.com

This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology

 13 12 2022 2022 12 1069999 14 10 2022 28 11 2022 Copyright © 2022 Zhao, Yi, Cao, Fu, Mei and Li 2022 Zhao, Yi, Cao, Fu, Mei and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy. By Zhao N, Yi Y, Cao W, Fu X, Mei N and Li C (2022) Front. Oncol. 12:923531. doi: 10.3389/fonc.2022.923531 biomarkers cytokines immunotherapy lung cancer immune related adverse events

In the published article, there was an error in the legend for Figure 12 and Figure 13 as published. There was a mistake in the legend for Figure 12 and Figure 13 , an incorrect description was used.

(A) Differences in IL-6 levels after the third cycle therapy between CB and UCB; (B) The nomogram based on logistic multivariate analysis.

(A) Differences in IL-8 levels after the third cycle therapy between CB and UCB; (B) The nomogram based on logistic multivariate analysis.

“ Figure 12 . (A) Differences in IL-6 levels after the second cycle therapy between CB and UCB; (B) The nomogram based on logistic multivariate analysis.” should be “ Figure 12 . (A) Differences in IL-6 levels after the third cycle therapy between CB and UCB; (B) The nomogram based on logistic multivariate analysis.”

“ Figure 13 (A) Differences in IL-8 levels after the second cycle therapy between CB and UCB; (B) The nomogram based on logistic multivariate analysis.” should be “ Figure 13 (A) Differences in IL-8 levels after the third cycle therapy between CB and UCB; (B) The nomogram based on logistic multivariate analysis.”

The corrected legend appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

In the published article, there was an error in Figure 3 as published. “81 patients had not been treated for six months at the end of follow-up and could not be analyzed for effectiveness.” should be “79 patients had not been treated for six months at the end of follow-up and could not be analyzed for effectiveness.”

The corrected Figure 3 and its caption appear below.

Selection process for patients.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.